Cagrilintide Phase 1 trial (NCT03600480)
Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Combination With Semaglutide in Subjects Being Overweight or With Obesity
At a glance
- Phase
- Phase 1
- Status
- Completed
- Enrolment
- 96
- actual
- Start
- 25 Jul 2018 (actual)
- Primary completion
- 12 Jun 2020 (actual)
- Sponsor
- Novo Nordisk A/S
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| NNC0174-0833+Semaglutide | Experimental | Drug: NNC0174-0833; Drug: Semaglutide | Participants will receive increasing doses of NNC0174-0833 along with semaglutide. The treatment period from first treatment (Day 1) to end of the treatment (Day 141) will be 20 weeks. |
| Placebo (NNC0174-0833)+Semaglutide | Active comparator | Drug: Semaglutide; Drug: Placebo (NNC0174-0833) | Participants will receive placebo (NNC0174-0833) along with semaglutide. The treatment period from first treatment (Day 1) to end of the treatment (Day 141) will be 20 weeks |
Primary endpoint
| Measure | Time frame |
|---|---|
| Number of treatment emergent adverse events (TEAEs) | From first administration of NNC0174-0833 (Day 1) to completion of the post-treatment follow-up (Day 176) |
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| AUC0-168h,AM833,SS: the area under the NNC0174-0833 plasma concentration-time curve from 0 to 168 hours at steady state | From last dose (Day 134) until end of treatment (Day 141) |
| Cmax,AM833,SS: the maximum concentration of NNC0174-0833 in plasma at steady state | From last dose (Day 134) until end of treatment (Day 141) |
| AUC0-168h,sema,SS: the area under the semaglutide plasma concentration-time curve from 0 to 168 hours at steady state | From last dose (Day 134) until end of treatment (Day 141) |
| Cmax,sema,SS: the maximum concentration of semaglutide in plasma at steady state | From last dose (Day 134) until end of treatment (Day 141) |
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 55 Years
Results
No results posted on ClinicalTrials.gov as of 11 Oct 2026.
How the cagrilintide plus semaglutide 2.4 mg combination was dosed in this trial
This single-centre study ran six overlapping cohorts, each randomising participants 3:1 to cagrilintide at one of six levels or to placebo, with semaglutide 2.4 mg given to everyone.[2]
The primary endpoint was the number of treatment-emergent adverse events from baseline to the end of follow-up.[2]
What the published paper reported for this early combination study
Across 566 adverse events in 92 participants, 207 (37%) were gastrointestinal disorders.[2]
Half-life was reported as 159-195 h for cagrilintide 0.16-4.5 mg and 145-165 h for semaglutide 2.4 mg.[2]
At week 20 the mean weight reduction was 17.1% with cagrilintide 2.4 mg versus 9.8% with pooled placebo, both on top of semaglutide 2.4 mg.[2]
Sources
- 1Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Combination With Semaglutide in Subjects Being Overweight or With ObesityClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 11 Oct 2026
- 2Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.Lancet (London, England) · 2021PMID 33894838Accessed 2 Oct 2026
Found an error? Report a correction.